Marketing-authorisation holder
Merck Sharp Dohme Ltd
36 medicines in 2 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder
36 medicines in 2 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 36
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BELSOMRA10mg | 15mg | 20mg | 5mg · Tablet | Suvorexant | United States | Marketed | 2014 |
| CELESTONE0.6mg/5ml · Syrup | Betamethasone | United States | Not marketed | 1964 |
| CRIXIVAN100mg base | 200mg base | 333mg base | 400mg base · Capsule | Indinavir | United States | Not marketed | 1996 |
| DUTREBIS150mg; 300mg base · Tablet | Lamivudine, Raltegravir | United States | Not marketed | 2015 |
| ENFLONSIA105mg/0.7ml · Injection | Clesrovimab | United States | Marketed | 2025 |
| Enflonsia | Clesrovimab | EU (EMA) | Authorised | 2026 |
| GUANIDINE HYDROCHLORIDE125mg · Tablet | Guanidine | United States | Not marketed | 1939 |
| JUVISYNC10MG; 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 10MG; 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG; 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness re · Tablet | Simvastatin, Sitagliptin | United States | Not marketed | 2011 |
| KEYTRUDA100mg/4ml (25mg/ml) · Solution | Pembrolizumab | United States | Marketed | 2014 |
| KEYTRUDA QLEX395mg/4800units(2.4ml) | 790mg/9600units(4.8ml) · Injectable | Pembrolizumab, Berahyaluronidase alfa-pmph | United States | Marketed | 2025 |
| LOTRISONE0.05% BASE; 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Lotion | Betamethasone, Clotrimazole | United States | Not marketed | 2000 |
| MINTEZOL500mg · Tablet, chewable | Tiabendazole | United States | Not marketed | 1967 |
| MINTEZOL500mg/5ml · Suspension | Tiabendazole | United States | Not marketed | 1967 |
| NOXAFIL300mg/16.7ml (18mg/ml) · Solution | Posaconazole | United States | Not marketed | 2014 |
| NOXAFIL100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, delayed release | Posaconazole | United States | Not marketed | 2013 |
| PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Famotidine | United States | Not marketed | 1994 |
| PREVYMIS240mg | 480mg · Tablet | Letermovir | United States | Marketed | 2017 |
| PREVYMIS240mg/12ml (20mg/ml) | 480mg/24ml (20mg/ml) · Solution | Letermovir | United States | Marketed | 2017 |
| REBETOL200MG **Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy** | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule | Ribavirin, Comarketed with interferon alfa-2b, Recombinant, Rebetron combination therapy** | United States | Not marketed | 1998 |
| STROMECTOL3MG | 6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Ivermectin | United States | Marketed | 1996 |
| TEMODAR100mg/vial · Powder | Temozolomide | United States | Marketed | 2009 |
| TEMODAR100mg | 140mg | 180mg | 20mg | 250mg | 5mg · Capsule | Temozolomide | United States | Not marketed | 1999 |
| VICTRELIS200mg · Capsule | Boceprevir | United States | Not marketed | 2011 |
| WELIREG40mg · Tablet | Belzutifan | United States | Marketed | 2021 |
| WINREVAIR45mg | 60mg · Injectable | Sotatercept | United States | Marketed | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 25 | 25 | 0 | CompaniesAll medicines |
| European Union (EMA) | 11 | 1 | 10 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.